All In Biotech

NDA 208712 · Sobi

Vonjo

Pacritinib Citrate · Oral · Kinase Inhibitor

NovelAccelerated approvalPriority reviewOrphan

CDER novel approval, Feb 28, 2022: To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets

Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Feb 28, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

52

3 Phase 3, 18 recruiting

FAERS reports

3,069

1,125 serious, 350 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 30, 2026.

VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10 9 /L. This indication is approved under accelerated approval based on spleen volume reduction [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). VONJO is a kinase inhibitor indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10 9 /L ( 1 ). This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Mechanism: Pacritinib is an oral kinase inhibitor with activity against wild type Janus associated kinase 2 (JAK2), mutant JAK2V617F, FMS-like tyrosine kinase 3 (FLT3), and interleukin 1 receptor associated kinase-1 (IRAK1) which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Pacritinib is also an inhibitor of activin A receptor, type 1/activin receptor like-kinase 2 (ACVR1/ALK2). MF is often associated with dysregulated JAK2 signaling. At clinically relevant concentrations, pacritinib does not inhibit JAK1. Pacritinib has...

Therapeutic areas: Oncology · Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 28, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterReviewLabel
1 products under this application
  • VONJO · PACRITINIB CITRATE EQ 100MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pacritinib" as an intervention, any sponsor and status, largest first.

All 52 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea651
  • off label use623
  • fatigue388
  • product dose omission issue337
  • death314
  • nausea304
  • platelet count decreased297
  • haemoglobin decreased213
  • asthenia158
  • dizziness132
  • drug ineffective119
  • splenomegaly109

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20173
20191
20201
20219
2022421
20231,102
2024750
2025493
2026288

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vonjo (Pacritinib Citrate)

2024 spending

$111M

Beneficiaries

1,046

5,065 claims

Per beneficiary

$105,945

$210.27 per unit

View as table
YearSpending
2020$0
2021$0
2022$37,696,367
2023$92,544,883
2024$110,818,538

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 17 on PubMed

Sponsor: Sobi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.